Leuzy, Antoine
Lund University
21 papers on CoChatORCID 0000-0003-4542-7879
Most cited papers
- Verified
Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 1,603
- Verified
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 628
- Verified
A multicentre validation study of the diagnostic value of plasma neurofilament light.
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., et al. (2021) · Nature Communications
Dementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research
Cited by 545
- Verified
[18F]FDG PET signal is driven by astroglial glutamate transport
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience
Neuroscience and Neuropharmacology ResearchMedical Imaging Techniques and Applications
Cited by 343
- Verified
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 311
- Verified
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders
Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 222
- Verified
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 188
- Verified
Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations
Cullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., et al. (2020) · Nature Aging
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 187
- Verified
Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
Ashton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 172
- Verified
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 149
- Verified
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Ashton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 142
- Verified
Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
Leuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 128
- Verified
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation
Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatments
Cited by 121
- Verified
The implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 114
- Verified
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 88
- Verified
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
Hall, S., Janelidze, S., Londos, E., Leuzy, A., Stomrud, E., Dage, J. L., & Hansson, O. (2021) · Movement Disorders
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 80
- Verified
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience
Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research
Cited by 77
- Verified
Developments in Tau PET Imaging
Zimmer, E. R., Leuzy, A., Gauthier, S., & Rosa-Neto, P. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 60
- Verified
Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 60
- Verified
Use of amyloid PET across the spectrum of Alzheimer’s disease: clinical utility and associated ethical issues
Leuzy, A., Zimmer, E. R., Heurling, K., Rosa-Neto, P., & Gauthier, S. (2014) · Amyloid
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 31
- Verified
In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals
Zimmer, E. R., Leuzy, A., Bhat, V., Gauthier, S., & Rosa-Neto, P. (2014) · Translational Neurodegeneration
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 30
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free